Skip to main content

Medical AI

Category: AI in Healthcare

A specialized medical AI developer focused on transforming standard 10-second ECG signals into powerful diagnostic tools for cardiovascular diseases using proprietary deep learning algorithms. Medical AI was founded in 2019. The company is led by Junmyung Kwon. Based in Seoul, South Korea. Team size: 53. Total funding raised: $11.3M. Latest round: Series B / Pre-IPO. Key investors include ["New Paradigm Investment","LB Investment","Naver D2SF","Naver Cloud","Bodyfriend"].

Founded
2019
Headquarters
Seoul, South Korea
Team size
53
Total funding
$11.3M

Value proposition

Enables non-invasive, rapid, and cost-effective screening of complex cardiac conditions like heart failure and myocardial infarction, which traditionally require expensive imaging or blood tests.

Products and solutions

["AiTiALVSD: AI software for detecting Left Ventricular Systolic Dysfunction (heart failure) from standard ECGs.","AiTiAMI: AI-based assistant for diagnosing Acute Myocardial Infarction (AMI).","AiTiA ECG Center: A platform for managing and analyzing large-scale cardiac biosignals.","Smartwatch ECG Analysis: Research-stage technology for early cardiac risk detection via wearable devices."]

Unique value

The first Korean company to receive medical device approval and 'Innovative Medical Technology' designation for AI-based heart failure detection, achieving over 300,000 paid users within months of commercial launch.

Target customer

Tertiary and general hospitals, health examination centers, public health institutions, and smart device manufacturers.

Industries served

["Healthcare & Medical Diagnostics","Digital Health","Biotechnology","Public Procurement"]

Technology advantage

Recognized as a 'National Strategic Technology' by the Korean government; their algorithms demonstrated the world's highest accuracy in head-to-head validation studies at Amsterdam University Medical Center.

How they differentiate

Medical AI differentiates itself by transforming a simple 10-second ECG signal into a comprehensive diagnostic tool for complex conditions like heart failure (LVSD) and myocardial infarction, which traditionally require expensive imaging. It leverages its origins as a spin-off from Sejong Hospital to access high-quality, large-scale clinical biosignal data.

Main competitors

["Vuno (DeepCARS)","DeepCardio","Anumana (Mayo Clinic spin-off)","Lunit"]

Key partnerships

["Sejong Medical Group (Original spin-off partner and clinical validation site)","Bodyfriend (Strategic investor and wellness device partner)","Naver D2SF / Naver Cloud (AI infrastructure and investment)","Public Procurement Service (Designated as an 'Innovative Product' for government supply)"]

Notable customers

["Samsung Electronics (Galaxy Watch collaboration)","Bodyfriend","Sejong Hospital Group","Public Procurement Service (Korea)"]

Major milestones

["Founded in 2019 as a spin-off from Sejong Hospital","Designated as a 'National Strategic Technology' by the Korean government","Received first-ever Korean medical device approval for AI heart failure detection (2024)","Designated as an 'Innovative Product' by the Public Procurement Service for government supply","Achieved Grade A/A in technical evaluation for KOSDAQ listing (2024)"]

Growth metrics

Reached over 300,000 cumulative paid users within 3 months of launching its heart failure detection solution (AiTiALVSD).

Market positioning

Leading specialized biosignal AI challenger in the cardiovascular diagnostic space.

Geographic focus

South Korea (primary), North America, Europe (clinical validation and research focus).

Patents and IP

Holds multiple proprietary AI algorithms for ECG biosignal analysis; technology officially verified as a national strategic asset in the advanced biotech sector.

About Junmyung Kwon

Junmyung Kwon is an Emergency Medicine specialist and an alumnus of Seoul National University College of Medicine. Before founding Medical AI, he served as the Chief of the Critical Care and Emergency Department and the Head of the AI Big Data Center at Sejong Medical Group. He was a primary collaborator in developing Vuno's AI-based cardiac arrest prediction device, 'DeepCARS', and is recognized as a top expert in medical biosignal AI research.

Official website: